US 12,304,900 B2
Islet cell manufacturing compositions and methods of use
Austin Thiel, Southborough, MA (US); Jihad Yasin, Gardner, MA (US); Evrett Thompson, Wobum, MA (US); and Felicia J. Pagliuca, Boston, MA (US)
Assigned to Vertex Pharmaceuticals Incorporated, Boston, MA (US)
Filed by Vertex Pharmaceuticals Incorporated, Boston, MA (US)
Filed on Feb. 20, 2024, as Appl. No. 18/581,700.
Application 18/581,700 is a division of application No. 16/864,886, filed on May 1, 2020, granted, now 11,945,795.
Application 16/864,886 is a continuation of application No. PCT/US2018/061364, filed on Nov. 15, 2018.
Claims priority of provisional application 62/669,170, filed on May 9, 2018.
Claims priority of provisional application 62/586,808, filed on Nov. 15, 2017.
Prior Publication US 2024/0294501 A1, Sep. 5, 2024
Int. Cl. C07D 401/14 (2006.01); C07D 401/04 (2006.01); C07K 14/495 (2006.01); C07K 14/50 (2006.01); C12N 5/071 (2010.01)
CPC C07D 401/14 (2013.01) [C07D 401/04 (2013.01); C07K 14/495 (2013.01); C07K 14/50 (2013.01); C12N 5/0676 (2013.01); C12N 2501/117 (2013.01); C12N 2501/155 (2013.01); C12N 2501/16 (2013.01); C12N 2501/385 (2013.01); C12N 2501/41 (2013.01)] 24 Claims
 
1. A composition comprising a population of PDX1-negative primitive gut tube cells and a BMP signaling pathway inhibitor, wherein the BMP signaling pathway inhibitor is a compound of Formula A,

OG Complex Work Unit Chemistry